Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study
In this real-world population, most participants initiated finerenone at 10 mg and remained on that dose. Finerenone was well tolerated and safety was consistent with the known profile of the drug. This interim analysis and future data from FINE-REAL will help to guide decision-making regarding the use of finerenone in participants with CKD and T2D.
Authors
- Susanne B. Nicholas (ORCID: https://orcid.org/0000-0003-3535-9120)
- Martin Merz
- Andrea Horvat-Broecker
- David C. Wheeler (ORCID: https://orcid.org/0000-0001-8121-5182)
- Christoph Wanner (ORCID: https://orcid.org/0000-0001-9507-5301)
- Charlie Scott (ORCID: https://orcid.org/0000-0002-2816-4889)
- Nihar R. Desai (ORCID: https://orcid.org/0000-0003-2384-2545)
- Nan Hee Kim (ORCID: https://orcid.org/0000-0003-4378-520X)
- Zihe Zheng (ORCID: https://orcid.org/0000-0003-0040-4016)
- Ricardo Correa-Rotter
- Sankar Dass Navaneethan (ORCID: https://orcid.org/0000-0002-4953-7795)
- Kevin M. Pantalone (ORCID: https://orcid.org/0000-0002-3897-4551)
- Lixin Guo (ORCID: https://orcid.org/0000-0003-2596-8387)
Institutions
- Cleveland Clinic (US)
- Yale New Haven Hospital (US)
- Bayer (United States) (US)
- University of California, Los Angeles (US)
- Baylor College of Medicine (US)
- Korea University (KR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Kidney Research UK (GB)
- Yale University (US)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Universitätsklinikum Würzburg (DE)
- Korea University (JP)
- Bayer (United Kingdom) (GB)
- University College London (GB)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1093/ckj/sfaf305
- Primary Topic
- Anesthesia and Sedative Agents
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer